| Placebo | Aztreonam lysine | Tobramycin (nebulised) | Tobramycin + Fosfomycin (nebulised) | |
|---|---|---|---|---|
| Placebo | 0.3 (0.08, 0.92) | 3 (0.55, 24.66) | 0.9 (0.25, 3.81) | |
| Aztreonam lysine | 0.3 (0.08, 0.92) | |||
| Tobramycin (nebulised) | 3 (0.55, 24.66) | 10.43 (1.31, 122.2) | ||
| Tobramycin + Fosfomycin (nebulised) | 0.9 (0.25, 3.81) | 3.11 (0.55, 21.38) | 0.3 (0.03, 2.78) |
Results in the top right diagonal of the table are the mean differences and 95% CrI from the conventional meta-analyses of direct evidence between the column-defined treatments compared to the row-defined treatment. Mean differences greater than 0 favour the column-defined treatment.
Results in the bottom left are the mean differences and 95% CrI from the NMA model of direct and indirect evidence between the row-defined treatments compared to the column-defined treatments. Mean differences greater than 0 favour the row-defined treatment.
Numbers in bold denote results for which the 95% CrI does not include the null effect of 0
From: 9, Pulmonary monitoring, assessment and management
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.